酪酸梭菌肠球菌三联活菌片对肠易激综合征老年患者症状积分及炎症因子水平的影响

Effect of Clostridium butyricum Enterococcus triple viable tablets on symptom score and inflammatory factors in elderly patients with irritable bowel syndrome

目的:研究酪酸梭菌肠球菌三联活菌片对肠易激综合征老年患者症状积分及炎症因子水平的影响。方法:以2019年1月-2021年1月进行诊断并治疗的100例肠易激综合征患者作为研究对象,按照随机分组原则,将以上患者分为观察组及对照组,每组50例。2组患者均采取调整饮食、解痉止泻药物进行治疗,观察组患者在该基础上联合采用酪酸梭菌肠球菌三联活菌片,2组患者均治疗4周。比较2组患者的治疗效果、肠易激综合征症状尺度表评分(IBS-BSS)、肠道微生物情况、炎症反应水平、肠道屏障因子水平以及不良反应之间的差异。结果:观察组患者的总有效率(94.00%)显著高于对照组(80.00%),差异有统计学意义(χ^(2)=10.325,P<0.001);经过治疗,2组患者的IBS-BSS评分均显著下降,且观察组患者的IBS-BSS评分显著低于对照组(t=2.880,P=0.005);治疗后,患者的肠道双歧杆菌、肠球菌、乳酸杆菌显著升高,肠杆菌显著降低,且观察组患者的肠道双歧杆菌(t=2.125,P=0.036)、肠球菌(t=6.408,P<0.001)、乳酸杆菌(t=2.912,P=0.004)显著高于对照组,肠杆菌显著低于对照组(t=2.395,P=0.019);治疗后,2组患者的D-LA水平显著下降,MFG-E8水平显著升高,且观察组患者的D-LA水平显著低于对照组(t=6.335,P<0.001),MFG-E8水平显著高于对照组(t=7.115,P<0.001);治疗后,2组患者的IL-1β、TNF-α以及IL-6水平均显著下降,且观察组患者的IL-1β(t=15.045,P<0.001)和TNF-α(t=3.329,P=0.001)以及IL-6水平(t=2.239,P=0.027)显著低于对照组;2组患者治疗期间口干、便秘以及恶心的发生率比较差异无统计学意义(P>0.05)。结论:肠易激综合征老年患者采用酪酸梭菌肠球菌三联活菌片进行治疗,肠道屏障功能显著恢复,炎症反应水平下降,治疗效果显著。

Objective: To study the effect of Clostridium butyricum Enterococcus triple viable tablets on symptom score and inflammatory factors in elderly patients with irritable bowel syndrome. Methods: In this prospective study, 100 patients with irritable bowel syndrome diagnosed and treated from January 2019 to January 2021 were selected as the research objects. According to the principle of random grouping, the above patients were randomly divided into the observation group and the control group, with 50 cases in each group. The two groups were treated with diet adjustment and antispasmodic and antidiarrheal drugs, and the patients in the observation group were randomly divided into two groups on the basis of the combination of Clostridium butyricum and Enterococcus triple viable tablets, both groups were treated for 4 weeks. The therapeutic effect, IBS-BSS score, intestinal microflora, inflammatory reaction level, barrier factor level and adverse reactions were compared between the two groups. Results: The total effective rate of the observation group(94.00%) was significantly higher than that of the control group(80.00%), the difference was statistically significant(χ^(2)=10.325, P<0.001);After treatment, the IBS-BSS scores of the two groups were significantly decreased, and the IBS-BSS score of the observation group was significantly lower than that of the control group(t=2.880, P=0.005);The intestinal Bifidobacterium, Enterococcus and Lactobacillus of the two groups were significantly increased in the observation group, Bifidobacterium(t=2.125, P=0.036), Enterococcus(t=6.408, P<0.001) and Lactobacillus(t=2.912, P=0.004) were significantly higher than those in the control group, and Enterobacter was significantly lower than those in the control group(t=2.395, P=0.019);D-LA in the two groups was significantly decreased, MFG-E8 was significantly increased, and D-LA in the observation group was significantly lower than that in the control group(the levels of IL-1β, TNF-α and IL-6 in the two groups were significantly decreased, and the levels of IL-1β(t=15.045, P<0.001), TNF-α(t=3.329, P=0.001) and IL-6(t=2.239, P=0.027) in the observation group were significantly lower than those in the control group;there was no significant difference in dry mouth, constipation and nausea between the two groups during treatment.The difference was statistically significant(P>0.05). Conclusion: The elderly patients with irritable bowel syndrome were treated with Clostridium butyricum and Enterococcus triple viable tablets, the intestinal barrier function was significantly restored, the level of inflammatory reaction was decreased, and the treatment effect was significant.